Bark Betzel1, Jens Homan2, Edo O Aarts2, Ignace M C Janssen2, Hans de Boer3, Peter J Wahab4, Marcel J M Groenen4, Frits J Berends2. 1. Department of Surgery, Rijnstate Hospital, Postal Number 1190, 6800 TA, Arnhem, The Netherlands. bbetzel@rijnstate.nl. 2. Department of Surgery, Rijnstate Hospital, Postal Number 1190, 6800 TA, Arnhem, The Netherlands. 3. Department of Internal Medicine, Rijnstate Hospital, Arnhem, The Netherlands. 4. Department of Gastroenterology, Rijnstate Hospital, Arnhem, The Netherlands.
Abstract
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the current study was to determine its efficacy and safety profile. METHODS: Inclusion criteria for treatment with a DJBL were: age 18-70 years, BMI 28-45 kg/m2, and T2DM with a HbA1c > 48 mmol/mol. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included changes in blood pressure, lipids, and anti-diabetic medication. Predictive factors for success of treatment with the DJBL were determined. RESULTS: Between 2011 and 2014, 185 out of 198 patients successfully underwent a DJBL implantation procedure, with an intended implantation time of 12 months. In these 185 patients, body weight decreased by 12.8 ± 8.0 kg (total body weight loss of 11.9 ± 6.9 %, p < 0.001), HbA1c decreased from 67 to 61 mmol/mol (p < 0.001) despite a reduction in anti-diabetic medication, and blood pressure and serum lipid levels all decreased. In total, 57 (31 %) DJBLs were explanted early after a median duration of 33 weeks. Adverse events occurred in 17 % of patients. C-peptide ≥1.0 nmol/L and body weight ≥107 kg at screening were independent predictive factors for success. CONCLUSIONS: Treatment with the DJBL in T2DM patients with (morbid) obesity results in improvement in glucose control, a reduction in anti-diabetic medication, and significant weight loss. The largest changes are observed within the first 3-6 months. Initial C-peptide levels and body weight may help to select patients with the greatest chance of success.
BACKGROUND: The duodenal-jejunal bypass liner (DJBL) is an endoscopic treatment for patients with type 2 diabetes mellitus (T2DM) and (morbid) obesity. The aim of the current study was to determine its efficacy and safety profile. METHODS: Inclusion criteria for treatment with a DJBL were: age 18-70 years, BMI 28-45 kg/m2, and T2DM with a HbA1c > 48 mmol/mol. Primary outcomes were changes in HbA1c and body weight. Secondary outcomes included changes in blood pressure, lipids, and anti-diabetic medication. Predictive factors for success of treatment with the DJBL were determined. RESULTS: Between 2011 and 2014, 185 out of 198 patients successfully underwent a DJBL implantation procedure, with an intended implantation time of 12 months. In these 185 patients, body weight decreased by 12.8 ± 8.0 kg (total body weight loss of 11.9 ± 6.9 %, p < 0.001), HbA1c decreased from 67 to 61 mmol/mol (p < 0.001) despite a reduction in anti-diabetic medication, and blood pressure and serum lipid levels all decreased. In total, 57 (31 %) DJBLs were explanted early after a median duration of 33 weeks. Adverse events occurred in 17 % of patients. C-peptide ≥1.0 nmol/L and body weight ≥107 kg at screening were independent predictive factors for success. CONCLUSIONS: Treatment with the DJBL in T2DM patients with (morbid) obesity results in improvement in glucose control, a reduction in anti-diabetic medication, and significant weight loss. The largest changes are observed within the first 3-6 months. Initial C-peptide levels and body weight may help to select patients with the greatest chance of success.
Authors: Eduardo G H de Moura; Bruno C Martins; Guilherme S Lopes; Ivan R Orso; Suzana L de Oliveira; Manoel P Galvão Neto; Marco A Santo; Paulo Sakai; Almino C Ramos; Arthur B Garrido Júnior; Marcio C Mancini; Alfredo Halpern; Ivan Cecconello Journal: Diabetes Technol Ther Date: 2011-09-20 Impact factor: 6.118
Authors: Parviez Koehestanie; Charlotte de Jonge; Frits J Berends; Ignace M Janssen; Nicole D Bouvy; Jan Willem M Greve Journal: Ann Surg Date: 2014-12 Impact factor: 12.969
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Ruben Schouten; Carianne S Rijs; Nicole D Bouvy; Wim Hameeteman; Ger H Koek; Ignace M C Janssen; Jan-Willem M Greve Journal: Ann Surg Date: 2010-02 Impact factor: 12.969
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Norbert Joachim Tripolt; Felix Aberer; Jasmin Url; Christoph Högenauer; Florian Schreiber; Andreas Eherer; Caren Sourij; Anna-Maria Obermayer; Vanessa Stadlbauer; Eva Svehlikova; Martina Brunner; Harald Kojzar; Peter Nikolaus Pferschy; Thomas Rudolf Pieber; Harald Sourij Journal: Diabetes Ther Date: 2018-12-11 Impact factor: 2.945
Authors: B Betzel; M I Cooiman; E O Aarts; I M C Janssen; P J Wahab; M J M Groenen; J P H Drenth; F J Berends Journal: Surg Endosc Date: 2019-03-14 Impact factor: 4.584
Authors: Selwyn van Rijn; Bark Betzel; Charlotte de Jonge; David P J van Dijk; Ignace M Janssen; Frits J Berends; Nicole D Bouvy; Jan Willem M Greve Journal: Obes Surg Date: 2018-05 Impact factor: 4.129
Authors: Hassan Ghoz; Veeravich Jaruvongvanich; Reem Matar; Azizullah Beran; Daniel B Maselli; Andrew C Storm; Barham K Abu Dayyeh Journal: Clin Transl Gastroenterol Date: 2020-09 Impact factor: 4.396